Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists

Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy

(2015) Jean-Claude Chomel et al.   Oncotarget

Targeting STAT5 in Hematologic Malignancies through Inhibition of the Bromodomain and Extra-Terminal (BET) Bromodomain Protein BRD2

(2014) S. Liu et al.   MOLECULAR CANCER THERAPEUTICS

Cited2 in hematopoietic stem cell function

(2013) Jinwei Du et al.   CURRENT OPINION IN HEMATOLOGY

HIF-1  deletion partially rescues defects of hematopoietic stem cell quiescence caused by Cited2 deficiency

(2012) J. Du et al.   BLOOD

Peroxisome proliferator–activated receptor activation increases imatinib uptake and killing of chronic myeloid leukemia cells

(2012) Lihui Wang et al.   EXPERIMENTAL HEMATOLOGY

A PML–PPAR-δ pathway for fatty acid oxidation regulates hematopoietic stem cell maintenance

(2012) Keisuke Ito et al.   NATURE MEDICINE

Quantitative trait mapping reveals a regulatory axis involving peroxisome proliferator-activated receptors, PRDM16, transforming growth factor- 2 and FLT3 in hematopoiesis

(2011) S. Avagyan et al.   BLOOD

Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis

(2011) H. Yuan et al.   BLOOD

Identification of HIF2  as an important STAT5 target gene in human hematopoietic stem cells

(2011) S. Fatrai et al.   BLOOD

Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method

(2010) T.-C. Chou   CANCER RESEARCH

Stat5 is indispensable for the maintenance ofbcr/abl-positive leukaemia

(2010) Andrea Hoelbl et al.   EMBO Molecular Medicine

Repression of β-catenin signaling by PPARγ ligands

(2010) Desheng Lu et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity

(2010) Amie S. Corbin et al.   JOURNAL OF CLINICAL INVESTIGATION

Conditional deletion of STAT5 in adult mouse hematopoietic stem cells causes loss of quiescence and permits efficient nonablative stem cell replacement

(2009) Z. Wang et al.   BLOOD

Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction

(2009) Ji Luo et al.   CELL

Imatinib assay by HPLC with photodiode-array UV detection in plasma from patients with chronic myeloid leukemia: Comparison with LC-MS/MS

(2009) Olivia Roth et al.   CLINICA CHIMICA ACTA

Abnormalities in Glucose Uptake and Metabolism in Imatinib-Resistant Human BCR-ABL-Positive Cells

(2009) D. J. Kominsky et al.   CLINICAL CANCER RESEARCH

Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia

(2009) Yaoyu Chen et al.   NATURE GENETICS

Imatinib for Newly Diagnosed Patients With Chronic Myeloid Leukemia: Incidence of Sustained Responses in an Intention-to-Treat Analysis

(2008) Hugues de Lavallade et al.   JOURNAL OF CLINICAL ONCOLOGY